SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms (BITF) is trending due to a recently announced offering of convertible senior notes, initially $300M then increased to $500M, intended to fund corporate needs and hedge against share dilution. While some investors express concerns about potential dilution and management decisions, others view the capital raise as a strategic move to fund expansion into AI and high-performance computing (HPC). The community is actively debating the offering's terms, potential impact, and the company's long-term prospects in the crypto mining and AI sectors.

ZenaTech, Inc. is an enterprise software technology company, which specializes in mission-critical cloud-based applications integrated with smart hardware to deliver solutions across diverse industries. The firm also develops drone manufacturing, sales, and distribution business. The company was founded by Shaun A. Passley on August 31, 2017 and is headquartered in Vancouver, Canada.

ZenaTech Inc.

ZenaTech is trending due to its plans for congressional meetings to promote drone technology and US manufacturing, sparking community interest in its potential impact on securing funding and shaping policy. Community members are discussing the company's strong management, vision, and possible comparison to Droneshield's growth, while highlighting the increasing US government spending on defense drone contracts. The company's focus on AI drones in the growing defense sector is also a key talking point.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending downwards, sparking heated debate among traders about whether this is a buying opportunity or the start of a significant correction. Community discussions revolve around potential price targets, the CEO's past stock sales, and the company's valuation relative to its revenue. Some traders express concerns about the broader market conditions and potential dilution, while others remain optimistic about the long-term prospects of quantum computing.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as traders assess market volatility amidst concerns about regional banks and the potential for a trade war with China. Community discussions revolve around potential support levels and whether the market will experience a significant downturn or a bounce. Increasing VIX levels and rising gold prices add to the uncertain outlook, with some participants bracing for a potential market correction.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors assess its shift from Bitcoin mining to AI cloud infrastructure, particularly after closing a significant convertible notes deal. The community is discussing the company's potential for growth in the AI sector, its partnership with NVDA, and whether recent price pullbacks present a buying opportunity, alongside debates about its valuation.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community debates its role as a safe haven asset amid broader market volatility and a surge in gold prices; recent price action has spurred discussions about potential support levels and future market direction. Mixed sentiment prevails, with some traders pointing to technical indicators suggesting a potential bounce, while others express concern about potential further declines. Community members are actively discussing the impact of large short positions and potential market manipulation.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders discuss potential market volatility amidst concerns about trade tensions and economic uncertainty. Community members are actively debating whether to buy, sell, or hold, with some anticipating a significant market downturn while others express skepticism. The ETF's movements are being closely watched as a hedge against broader market risks.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending due to volatility following a recent equity offering, with community debates centering on whether it represents a smart growth play or shareholder dilution. Discussions also involve the potential impact of broader market factors like rising U.S.-Venezuela tensions and government shutdowns, while some traders express confidence in the company's long-term drone and AI technology prospects.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending as the stock price surges, driven by positive news, including being named a leader in Everest Group's Conversational AI PEAK Matrix Assessment. The community is closely watching for a potential short squeeze as the stock approaches its all-time high, with many anticipating a strong earnings report in November.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences N.V.

ATAI Life Sciences is trending due to a recent public offering and FDA breakthrough therapy designation for its depression drug, BPL-003, driving both excitement and concerns about potential dilution. The community is actively debating the strategic implications of the offering, balancing short-term price pressure with the long-term benefits of extended funding for clinical trials. Broader sector tailwinds, including increasing recognition of psychedelic therapies, also contribute to investor interest.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter spiked around Invivyd on Monday after the company said its monoclonal antibodies pemivibart and VYD2311 continued to neutralize the emerging XFG variant of COVID-19 in laboratory tests.The company reported that both antibodies remained effective against XFG, which U.S. Centers for Disease Control and Prevention data and wastewater surveillance suggest is driving a rising wave of infections in the U.S.&nbsp;Similar results were shown against other circulating variants, including NB.1.8.1, LF.7.9 and LP.8.1. Invivyd said it identified no resistant strains.The data will be submitted to the U.S. Food and Drug Administration (FDA) for planned inclusion in the fact sheet for pemivibart, which is currently authorized under emergency use for pre-exposure prevention of COVID-19 in certain immunocompromised patients.The update follows news last week that Invivyd reached alignment with the FDA on a streamlined regulatory pathway for VYD2311.&nbsp;In a recent Type C meeting, the agency advised that a single Phase 2/3 randomized, placebo-controlled trial with a relatively modest number of symptomatic COVID-19 cases could support a biologics license application.&nbsp;Invivyd said it plans to test two doses of VYD2311 and has clinical supply on hand.Infections are growing or likely growing in 34 states, with wastewater data showing high or very high viral levels in 12 states, the company said, citing CDC forecasts.&nbsp;Invivyd said the structural target of its antibodies has remained stable across major variants since Omicron BA.2, supporting continued neutralization activity.On Stocktwits, retail sentiment for Invivyd was ‘bullish’ amid a 175% surge in 24-hour message volume.One user noted they had seen Invivyd fall to $0.48 before quickly rebounding above $1, adding that good timing was the only way to make money with the stock.&nbsp;<stembedurl>https://stocktwits.com/Jack696/message/625670790</stembedurl>Another user said they had added to their position at $0.61.<stembedurl>https://stocktwits.com/alexx013/message/625643913</stembedurl><a href="https://stocktwits.com/symbol/IVVD">Invivyd’s stock</a> has risen 31% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Invivyd’s (IVVD) stock has risen 31% so far in 2025. (Photo credit: Getty Images)

Retail Chatter Surges Around Invivyd After Data Show Pemgarda Neutralizes XFG COVID-19 Variant

The company also recently aligned with the FDA on a streamlined path to potential approval for its next-generation antibody VYD2311.

Equity

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -200.00% and -23.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of +17.95% and +57.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of +33.33% and +177.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Retail buzz around Invivyd Inc. spiked on Monday after it revealed its launch of a discovery program to create a measles-specific monoclonal antibody.&nbsp;Healthcare providers managing measles patients and outbreak situations contacted Invivyd to explore access to its prospective medicine since no approved treatments or post-exposure prophylaxis options exist for measles.Invivyd shares surged 29.7% on Monday to close at $0.84.Currently, clinicians lack numerous treatment options for managing measles cases.&nbsp;Children who have contracted measles receive high-dose Vitamin A to aid their recovery process, especially when their bodies lack Vitamin A.&nbsp;While high-dose Vitamin A therapy helps treat measles in children who have a deficiency of the vitamin, it shows potential liver toxicity and remains underutilized.&nbsp;Human donor-derived pooled plasma immune globulin (IVIG) is a mix of different antibodies from several donors that hasn't been officially approved, and its inconsistent makeup makes it less reliable for widespread use.Measles vaccines stand as the best protective measure available, yet their effectiveness diminishes because some populations fail to access or refuse them, leaving unprotected gaps after exposure to the virus.&nbsp;The latest research indicates that diseases like measles, which were previously under control, could reemerge and lead to serious outcomes such as pneumonia, encephalitis,&nbsp; and long-lasting immunological consequences.The monoclonal antibody discovery program of Invivyd would grow its portfolio, which presently contains next-generation treatments for COVID-19, respiratory syncytial virus (RSV), and influenza.&nbsp;Retail sentiment around Invivyd turned ‘extremely bullish’, with a 4,800% spike in 24-hour message volume.&nbsp;Some users expressed confidence that the stock could reach multiple dollars, while others pointed to monoclonal antibodies as the “future of medicine.”<stembedurl>https://stocktwits.com/trader2sde/message/614373951</stembedurl><stembedurl>https://stocktwits.com/TheFnFortune/message/614327973</stembedurl>The stock has risen 74.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’

Invivyd unveiled a discovery program for a measles-targeted monoclonal antibody, responding to provider demand amid a lack of approved treatments or post-exposure options. 

These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

This Penny Stock Just Doubled on Clinical Trial Results. Analysts Think It Can Surge 266% From Here.

Investors could consider this penny stock after its COVID-19 antibody breakthrough sent shares soaring, and analysts see massive triple-digit gains ahead.

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (OtherTLPPF) and Invivyd (IVVD)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Telix Pharmaceuticals Ltd. (TLPPF Research Report) and Invivyd...

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

Invivyd Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.75
Prev Close	$1.75
Open	$1.72
Dividend Yield	0.00%
50-Day Moving Average	$1.11
Beta	1.36
Avg. Volume	3.4M
PE Ratio	-1.90

52-Week High	$2.74
52-Week Low	$0.3546
Market Capitalization	$375.22M
EPS (Annual)	-$1.43
Price to Book	4.91
Revenue Per Employee	$256,404.04
Enterprise Value/EBITDA	N/A

IVVD
Invivyd Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IVVD News

IVVDInvivyd Inc